



KAMUYU AYDINLATMA PLATFORMU

EİS ECZACIBAŞI İLAÇ SİNAİ VE FİNANSAL YATIRIMLAR SANAYİ VE TİCARET A.Ş. Material Event Disclosure (General)

Summary

Investment Decision of Our Joint Venture Eczacıbaşı Monrol

Material Event Disclosure General

Related Companies []

Related Funds []

Material Event Disclosure General	
Update Notification Flag	Hayır (No)
Correction Notification Flag	Hayır (No)
Date Of The Previous Notification About The Same Subject	-
Postponed Notification Flag	Hayır (No)
Announcement Content	
Explanations	

In the Board of Directors meeting held on September 11,2023, our joint Venture Eczacıbaşı Monrol Nükleer Ürünler San. ve Tic. A.Ş. ("Eczacıbaşı Monrol") has decided to invest approximately 35.000.000 (thirty-five million) Euros to increase its production capacity in response to the growing global demand for n.c.a. Lu-177 (*) (non-carrier-added Lu-177) which Eczacıbaşı Monrol is currently producing. This capacity expansion will be phased in and completed by 2026.

The investment includes the expansion of existing production lines at Eczacıbaşı Monrol Gebze facility, as well as the establishment of a new production facility at the Gebze campus.

With this investment Eczacıbaşı-Monrol aims to produce n.c.a. Lu-177 in compliance with US and EU standards, using advanced technology applications, for distribution in global markets.

(*)n.c.a. Lu-177 is the radionuclide that forms the basis of radioligand therapy, is administered to patients intravenously by binding to target-specific receptor molecules. It is primarily used in the treatment of neuroendocrine and prostate cancers. Pharmaceutical manufacturers are also conducting research to explore its use in the treatment of other types of cancers.

This statement has been translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this disclosure statement, the Turkish version shall prevail.

We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.